TY - JOUR
T1 - Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation
AU - on behalf of the Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group
AU - Kuno, Masatomo
AU - Yamasaki, Satoshi
AU - Fujii, Nobuharu
AU - Ishida, Yasushi
AU - Fukuda, Takahiro
AU - Kataoka, Keisuke
AU - Uchida, Naoyuki
AU - Katayama, Yuta
AU - Sato, Maho
AU - Onai, Daishi
AU - Miyamoto, Toshihiro
AU - Ota, Shuichi
AU - Yoshioka, Satoshi
AU - Ara, Takahide
AU - Hangaishi, Akira
AU - Hashii, Yoshiko
AU - Onizuka, Makoto
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
AU - Inamoto, Yoshihiro
N1 - Funding Information:
This study was supported by the Japan Society for the Promotion of Science (18K08345).
Funding Information:
Keisuke Kataoka reports research funds from Otsuka Pharmaceutical, Chordia Therapeutics, Chugai Pharmaceutical, Takeda Pharmaceutical, and Bristol‐Myers Squibb, scholarship endowments from Eisai, Ono Pharmaceutical, Kyowa Kirin, Chugai Pharmaceutical, Takeda Pharmaceutical, Mochida Pharmaceutical, and JCR Pharmaceuticals, stock from Asahi Genomics, and a patent for Genetic alterations as a biomarker in T‐cell lymphomas and a patent for PD‐L1 abnormalities as a predictive biomarker for immune checkpoint blockade therapy outside the submitted work. Naoyuki Uchida reports honoraria from Chugai Pharmaceutical, Astellas Pharma, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, and Novartis Pharma outside the submitted work. Toshihiro Miyamoto reports honoraria from Takeda Pharmaceutical, Otsuka Pharmaceutical, MSD, Bristol‐Myers Squibb, Astellas Pharma, AbbVie, and Amgen Astellas BioPharma outside the submitted work. Shuichi Ota reports honoraria from Novartis outside the submitted work. Yoshihiro Inamoto reports honoraria from Novartis, Janssen, and Meiji Seika Pharma outside the submitted work. All other authors have no conflicts of interest to disclose.
Publisher Copyright:
© 2021 Wiley Periodicals LLC.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - We compared characteristics of myeloid neoplasms (MNs) following allogeneic hematopoietic cell transplantation (HCT) versus autologous HCT using a Japanese HCT registry database. Among 43 788 patients who underwent allogeneic (n = 18 874) or autologous HCT (n = 24 914) for non-myeloid malignancies or non-malignant diseases, 352 developed MNs. The cumulative incidence of MNs was lower after allogeneic HCT than after autologous HCT (0.3% vs. 1.8% at 10 years, respectively, p <.001). Compared with autologous HCT, MNs following allogeneic HCT developed in younger patients (median, 42 vs. 57 years old, respectively) and sooner after HCT (median, 16 vs. 33 months, respectively). Approximately half of MNs following allogeneic HCT were donor-derived and occurred later than recipient-derived MNs (median, 26 vs. 6 months, respectively, p =.003). In multivariate analysis, reduced-intensity conditioning and cord blood transplantation were associated with MN development after allogeneic HCT. Overall survival was similar in patients who developed MNs following allogeneic versus autologous HCT (18% vs. 22% at 5 years, respectively, p =.48). Patient age ≥ 55 years, the presence of previous HCT, AML subtype, and chromosome 5 or 7 abnormalities were adverse factors for overall survival after MN diagnosis. Further research is warranted to elucidate the mechanisms of MN development following allogeneic HCT.
AB - We compared characteristics of myeloid neoplasms (MNs) following allogeneic hematopoietic cell transplantation (HCT) versus autologous HCT using a Japanese HCT registry database. Among 43 788 patients who underwent allogeneic (n = 18 874) or autologous HCT (n = 24 914) for non-myeloid malignancies or non-malignant diseases, 352 developed MNs. The cumulative incidence of MNs was lower after allogeneic HCT than after autologous HCT (0.3% vs. 1.8% at 10 years, respectively, p <.001). Compared with autologous HCT, MNs following allogeneic HCT developed in younger patients (median, 42 vs. 57 years old, respectively) and sooner after HCT (median, 16 vs. 33 months, respectively). Approximately half of MNs following allogeneic HCT were donor-derived and occurred later than recipient-derived MNs (median, 26 vs. 6 months, respectively, p =.003). In multivariate analysis, reduced-intensity conditioning and cord blood transplantation were associated with MN development after allogeneic HCT. Overall survival was similar in patients who developed MNs following allogeneic versus autologous HCT (18% vs. 22% at 5 years, respectively, p =.48). Patient age ≥ 55 years, the presence of previous HCT, AML subtype, and chromosome 5 or 7 abnormalities were adverse factors for overall survival after MN diagnosis. Further research is warranted to elucidate the mechanisms of MN development following allogeneic HCT.
UR - http://www.scopus.com/inward/record.url?scp=85119053626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119053626&partnerID=8YFLogxK
U2 - 10.1002/ajh.26401
DO - 10.1002/ajh.26401
M3 - Article
C2 - 34738245
AN - SCOPUS:85119053626
SN - 0361-8609
VL - 97
SP - 185
EP - 193
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 2
ER -